Sanofi Stock Euronext Paris
Stocks
SANNV
FR001400UEY9
Pharmaceuticals
OTC Markets Traded| Market Cap | 89.03B 103B 83.36B 76.26B 144B 9,773B 146B 975B 383B 4,883B 385B 377B 16,252B | P/E 2026 * |
11.8x | P/E 2027 * | 10.3x |
|---|---|---|---|---|---|
| Enterprise Value | 100B 116B 94.01B 85.99B 162B 11,020B 164B 1,100B 432B 5,506B 434B 425B 18,327B | EV / Sales 2026 * |
2.11x | EV / Sales 2027 * | 1.92x |
| Free-Float |
88.34% | Yield 2026 * |
5.73% | Yield 2027 * | 6.05% |
Last Transcript: Sanofi
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 57 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 65 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +3.51% | - | - | 103B | |
| +1.89% | +3.20% | +59.70% | +165.18% | 1,062B | |
| -0.24% | +0.45% | +50.64% | +52.02% | 619B | |
| -0.95% | -5.26% | +24.23% | +65.08% | 431B | |
| +1.74% | +5.12% | +49.22% | +40.34% | 358B | |
| +0.88% | +0.06% | +36.14% | +40.99% | 293B | |
| +1.15% | -5.05% | +9.53% | +10.18% | 247B | |
| -0.73% | +4.44% | +42.22% | +66.41% | 219B | |
| +3.73% | -0.60% | -1.36% | -44.17% | 200B | |
| -0.68% | -0.32% | +18.66% | +66.32% | 162B | |
| Average | +0.84% | -1.90% | +32.11% | +51.37% | 399.14B | |
| Weighted average by Cap. | +0.66% | -0.83% | +41.14% | +78.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.51B 54.74B 44.48B 40.69B 76.82B 5,215B 77.82B 520B 204B 2,605B 206B 201B 8,672B | 50.61B 58.32B 47.39B 43.35B 81.84B 5,555B 82.91B 554B 218B 2,776B 219B 214B 9,239B |
| Net income | 7.94B 9.15B 7.44B 6.8B 12.84B 872B 13.01B 86.99B 34.14B 436B 34.36B 33.61B 1,450B | 9.27B 10.68B 8.68B 7.94B 14.99B 1,017B 15.18B 102B 39.84B 508B 40.09B 39.22B 1,692B |
| Net Debt | 11.37B 13.1B 10.64B 9.74B 18.38B 1,248B 18.62B 125B 48.87B 623B 49.18B 48.11B 2,075B | 8.22B 9.47B 7.69B 7.04B 13.29B 902B 13.46B 90.01B 35.32B 451B 35.55B 34.78B 1,500B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
